These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 531687)

  • 41. Immunopathogenesis of multiple sclerosis: implications for treatment.
    Waldron-Lynch F; Hennessy MJ
    Ir Med J; 2004 Jan; 97(1):5-6. PubMed ID: 15055909
    [No Abstract]   [Full Text] [Related]  

  • 42. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside.
    Cendrowski W
    Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124
    [No Abstract]   [Full Text] [Related]  

  • 43. Not every patient with multiple sclerosis should be treated at time of diagnosis.
    Pittock SJ; Weinshenker BG; Noseworthy JH; Lucchinetti CF; Keegan M; Wingerchuk DM; Carter J; Shuster E; Rodriguez M
    Arch Neurol; 2006 Apr; 63(4):611-4. PubMed ID: 16606780
    [No Abstract]   [Full Text] [Related]  

  • 44. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation].
    Callegaro D; Lana-Peixoto MA; Moreira MA; Marchiori PE; Bacheschi LA; Arruda WO; Campos GB; Lino AM; Melo AS; Rocha FC; Ferreira ML; Ataide L; Maciel DR;
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):869-74. PubMed ID: 12364965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current methods of therapy in multiple sclerosis.
    Sibley WA
    Mod Treat; 1970 Sep; 7(5):918-29. PubMed ID: 4326377
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunosuppressive therapy for multiple sclerosis.
    Gauthier SA; Buckle GJ; Weiner HL
    Neurol Clin; 2005 Feb; 23(1):247-72, viii-ix. PubMed ID: 15661097
    [No Abstract]   [Full Text] [Related]  

  • 47. [New therapeutic possibilities for disseminated sclerosis?].
    Wanscher B; Sørensen PS
    Ugeskr Laeger; 1994 Oct; 156(43):6353-8. PubMed ID: 7810008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M; Ghezzi A; Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple sclerosis: an update and review.
    Plank NM
    J Neurosurg Nurs; 1979 Mar; 11(1):44-7. PubMed ID: 221623
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.
    Putzki N; Katsarava Z; Vago S; Diener HC; Limmroth V
    Eur Neurol; 2008; 59(3-4):136-42. PubMed ID: 18057900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunological treatment for multiple sclerosis.
    Lancet; 1989 Apr; 1(8640):699-701. PubMed ID: 2467148
    [No Abstract]   [Full Text] [Related]  

  • 53. Multiple sclerosis: following clues from cause to cure.
    MacLean HJ; Freedman MS
    Lancet Neurol; 2009 Jan; 8(1):6-8. PubMed ID: 19081501
    [No Abstract]   [Full Text] [Related]  

  • 54. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?
    Rouzaud C; Hautecoeur P; Donze C; Heinzlef O; Dinh A; ; Creange A; Abdullatif A; Audouin B; Tourbah A; Berger E; Bourre B; Brochet B; Mekies C; Cabre P; Papeix C; Casez O; Brassat D; Defer G; Derache N; De Seze J; Dive D; LePage E; Fromont A; Gouider R; Edan G; Pelletier J; Grimaud J; Guennoc AM; Camdessanché JP; Kwiatkowski A; Laplaud D; Lebrun C; Debouverie M; Coustans M; Gout O; La Rochelle OA; Heinzlef O; Ouallet JC; Cavelou P; Hautecoeur P; Labauge P; Vermersch P; Wiertlewski S; Vukusic S; Marignier R; Schluep M; Seeldrayers P; Slassi I; Stankoff B; Thaite F; Moreau T; Thouvenot E; Zephir H; Ciron J; Collongues N; Kerschen P; Cohen M; Gueguen A; Mathey G; Carra C; Bernady P; Faucheux JM; Planque E; Donze C; Ruet A; Mouzawakh C; Pittion S
    Mult Scler Relat Disord; 2017 Nov; 18():161-163. PubMed ID: 29141801
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term results of hyperbaric oxygen therapy in multiple sclerosis.
    James PB; Webster CJ
    Lancet; 1989 Aug; 2(8658):327. PubMed ID: 2569121
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunological treatment in multiple sclerosis.
    Lancet; 1980 Nov; 2(8201):953-4. PubMed ID: 6107593
    [No Abstract]   [Full Text] [Related]  

  • 57. [Multiple sclerosis].
    Araki Y
    Nihon Rinsho; 1970 Mar; 28 Suppl():804-5. PubMed ID: 5430882
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial: Multiple Sclerosis.
    Lancet; 1976 Jan; 1(7951):129-31. PubMed ID: 54642
    [No Abstract]   [Full Text] [Related]  

  • 59. "Impressive results" in stem cell treatment for multiple sclerosis.
    Mayor S
    BMJ; 2016 Jun; 353():i3269. PubMed ID: 27287399
    [No Abstract]   [Full Text] [Related]  

  • 60. Multiple sclerosis:therapeutic strategies.
    Scheinberg LC
    Ann Neurol; 1994; 36 Suppl():S122. PubMed ID: 8017872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.